BeiGene Clinical Pipeline - Solid Tumor

 PDF   2   05/2021

Para obtener más información sobre esta publicación, por favor envíe una solicitud de información médica.

We are advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is also working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients. We have three internally-developed late-stage clinical drug candidates, four marketed products in China and one marketed product in the U.S.

Rating

Rate this publication

¿Necesita más información?
Service